UiPath (NYSE:PATH) PT Raised to $30.00

UiPath (NYSE:PATH) had its target price increased by Bank of America from $26.00 to $30.00 in a research report released on Thursday, Benzinga reports. The firm currently has a buy rating on the healthcare company’s stock.

A number of other equities analysts also recently issued reports on the company. Evercore ISI increased their price target on UiPath from $24.00 to $27.00 and gave the stock an in-line rating in a research report on Thursday. TD Cowen raised their target price on UiPath from $25.00 to $28.00 and gave the stock an outperform rating in a research note on Thursday. DA Davidson lifted their price objective on UiPath from $20.00 to $24.00 and gave the company a neutral rating in a research note on Thursday. Mizuho lifted their target price on UiPath from $22.00 to $25.00 and gave the company a neutral rating in a report on Thursday. Finally, Barclays lifted their price target on UiPath from $23.00 to $25.00 and gave the stock an equal weight rating in a report on Friday. Nine research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of Hold and an average price target of $27.13.

UiPath Price Performance

UiPath stock traded up $0.32 during midday trading on Thursday, reaching $23.07. The company’s stock had a trading volume of 9,842,354 shares, compared to its average volume of 10,074,664. The stock’s 50-day simple moving average is $23.52 and its 200-day simple moving average is $20.70. The stock has a market capitalization of $13.06 billion, a P/E ratio of -135.46 and a beta of 0.97. UiPath has a 52-week low of $12.38 and a 52-week high of $27.87.

Insider Activity

In other news, CFO Ashim Gupta sold 70,000 shares of the business’s stock in a transaction that occurred on Monday, January 8th. The shares were sold at an average price of $23.02, for a total value of $1,611,400.00. Following the completion of the transaction, the chief financial officer now directly owns 788,148 shares in the company, valued at approximately $18,143,166.96. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. In related news, Director Rich Wong sold 200,000 shares of the stock in a transaction dated Monday, January 8th. The shares were sold at an average price of $23.12, for a total transaction of $4,624,000.00. Following the completion of the transaction, the director now owns 429,418 shares in the company, valued at $9,928,144.16. The transaction was disclosed in a document filed with the SEC, which is available through this link. Also, CFO Ashim Gupta sold 70,000 shares of the stock in a transaction dated Monday, January 8th. The stock was sold at an average price of $23.02, for a total transaction of $1,611,400.00. Following the transaction, the chief financial officer now owns 788,148 shares of the company’s stock, valued at approximately $18,143,166.96. The disclosure for this sale can be found here. Insiders sold a total of 411,000 shares of company stock valued at $9,418,670 in the last quarter. Company insiders own 31.03% of the company’s stock.

Institutional Inflows and Outflows

Several large investors have recently made changes to their positions in the business. Intech Investment Management LLC raised its position in shares of UiPath by 3.1% in the 4th quarter. Intech Investment Management LLC now owns 14,324 shares of the healthcare company’s stock worth $356,000 after purchasing an additional 426 shares during the last quarter. 180 Wealth Advisors LLC boosted its position in shares of UiPath by 0.3% during the 4th quarter. 180 Wealth Advisors LLC now owns 188,950 shares of the healthcare company’s stock valued at $4,497,000 after acquiring an additional 492 shares during the last quarter. Bleakley Financial Group LLC boosted its position in shares of UiPath by 4.9% during the 4th quarter. Bleakley Financial Group LLC now owns 12,691 shares of the healthcare company’s stock valued at $315,000 after acquiring an additional 598 shares during the last quarter. Simplicity Solutions LLC raised its holdings in UiPath by 4.9% during the 4th quarter. Simplicity Solutions LLC now owns 12,691 shares of the healthcare company’s stock valued at $315,000 after buying an additional 598 shares during the period. Finally, Creative Planning raised its holdings in UiPath by 7.0% during the 2nd quarter. Creative Planning now owns 10,163 shares of the healthcare company’s stock valued at $185,000 after buying an additional 666 shares during the period. 59.04% of the stock is owned by hedge funds and other institutional investors.

About UiPath

UiPath Inc provides an end-to-end automation platform that offers a range of robotic process automation (RPA) solutions primarily in the United States, Romania, and Japan. The company offers a suite of interrelated software to build, manage, run, engage, measure, and govern automation within the organization.